Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Clijsters L, Hoencamp C, Calis JJ, Marzio A, Handgraaf SM, Cuitiño MC, et al. Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs. Mol Cell. 2019;74(6):1264-1277.e7.

Donaldson K, Buchanich JM, Grigson PS, Deneke E, Donaldson K, Vrana KE, et al. Abstracts of Presentations at the Association of Clinical Scientists 139 Meeting Hershey, PA, May 15-18, 2019. Ann Clin Lab Sci. 2019;49(3):403-416.

Marino A, Zhang Y, Rubinelli L, Riemma MA, Ip JE, Di Lorenzo A. Pressure overload leads to coronary plaque formation, progression, and myocardial events in ApoE-/- mice. JCI Insight. 2019;4(9).

Gerges MM, Godil SS, Rumalla K, Liechty B, Pisapia DJ, Magge RS, et al. Genomic profile of a primary squamous cell carcinoma arising from malignant transformation of a pineal epidermoid cyst. Acta Neurochir (Wien). 2019;161(9):1829-1834.

Bander ED, Jones SH, Pisapia D, Magge R, Fine H, Schwartz TH, et al. Tubular brain tumor biopsy improves diagnostic yield for subcortical lesions. J Neurooncol. 2019;141(1):121-129.

Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T, et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep. 2019;26(12):3203-3211.e5.

Canver MC, Cushing MM, Vagelatos G, Vasovic LV. Visual evidence of a hemolytic transfusion reaction identified by blood bank testing after emergency blood transfusion. Transfusion. 2019;59(11):3301-3302.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2019.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019;17(2):446-456.

Hernandez A, Brandler TC, Zhou F, Moreira AL, Schatz-Siemers N, Simsir A. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma. Am J Clin Pathol. 2019;151(4):403-415.